SCHEMBL3500766

SCHEMBL3500766

CCC(=O)c1ccc(-c2ccc(F)cn2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.58
RXFP1 Q9HBX9 2/20 0.58
PTPN1 P18031 1/20 0.51
PTPN6 P29350 1/20 0.51
PTPN11 Q06124 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
RAB9A P51151 3/20 0.50
MAPT P10636 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TP53 P04637 2/20 0.48
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
MCHR1 Q99705 1/20 0.43
LDHA P00338 2/20 0.42
HTR7 P34969 1/20 0.42
BRS3 P32247 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27866841 0.83 SMN1; SMN2 (0.51) NPC1RXFP1SMN1; SMN2RAB9AMAPT
SCHEMBL3502067 0.82 NPC1 (0.63) NPC1RXFP1PTPN1PTPN6PTPN11
SCHEMBL26571653 0.80 NPC1 (0.65) NPC1RXFP1PTPN1PTPN6PTPN11
SCHEMBL11485192 0.79 SMN1; SMN2 (0.68) NPC1PTPN1SMN1; SMN2RAB9AMAPT
SCHEMBL16595760 0.79 NPC1 (0.51) NPC1RXFP1PTPN1PTPN6PTPN11
SCHEMBL16595344 0.78 NPC1 (0.61) NPC1RXFP1PTPN1PTPN6PTPN11
SCHEMBL655375 0.77 HTR7 (0.64) NPC1PTPN1SMN1; SMN2RAB9AMAPT
SCHEMBL3501796 0.77 NPC1 (0.56) NPC1RXFP1PTPN1PTPN6PTPN11
SCHEMBL10355354 0.77 HTR7 (0.65) NPC1RXFP1PTPN1PTPN6PTPN11
SCHEMBL3500804 0.76 NPC1 (0.59) NPC1RXFP1PTPN1PTPN6PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193228-B2 Substituted imidazole as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-06-05 US disclosed
US-8193228-B2 Substituted imidazole as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-06-05 US disclosed
US-8193228-B2 Substituted imidazole as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME CORP. (US) 2012-06-05 US disclosed
US-20100022598-A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME LLC 2010-01-28 US disclosed
US-20100022598-A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME LLC 2010-01-28 US disclosed
US-20100022598-A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators MERCK SHARP & DOHME LLC 2010-01-28 US disclosed
WO-2008051406-A2 SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS MERCK & CO., INC. (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022598-A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators BRS3, INSR, INSRR NPC1 1685/4885RXFP1 131/4885PTPN1 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.